
AbbVie
OrganizationHeard in 50 episodes across 17 shows since Oct 2025
AbbVie Inc. is a publicly traded American biopharmaceutical company headquartered in North Chicago, Illinois, spun off from Abbott Laboratories in 2013. It researches, develops, manufactures, and commercializes medicines across areas including immunology, oncology, neuroscience/CNS, aesthetics, and other specialty-care fields; the podcast discussions primarily reference its partnerships, business-development activity, CNS pipeline, and exposure to pharmaceutical patent expirations.
Episodes
This week
Expert statements
Share of the conversation
Mentions of AbbVie per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Aug 26 | 0.01‰ | 1 |
| Sep 28 | 0.01‰ | 1 |
| Oct 5 | 0.02‰ | 2 |
| Oct 6 | 0.03‰ | 1 |
| Oct 7 | 0.04‰ | 2 |
| Oct 9 | 0.06‰ | 2 |
| Oct 13 | 0.06‰ | 3 |
| Oct 16 | 0.05‰ | 3 |
| Oct 19 | 0.06‰ | 1 |
| Oct 22 | 0.05‰ | 2 |
| Oct 26 | 0.02‰ | 1 |
| Oct 27 | 0.03‰ | 1 |
| Oct 30 | 0.03‰ | 2 |
| Nov 4 | 0.03‰ | 2 |
| Nov 5 | 0.04‰ | 1 |
| Nov 9 | 0.07‰ | 6 |
| Nov 11 | 0.07‰ | 2 |
| Nov 13 | 0.08‰ | 2 |
| Nov 16 | 0.04‰ | 1 |
| Nov 17 | 0.05‰ | 1 |
| Nov 20 | 0.02‰ | 1 |
Email alert
Email me when AbbVie comes up on a podcast
One email a week at most, with the new episodes that mention AbbVie. Free, no account needed, unsubscribe in one click.
What experts have said about AbbVie
14 statements · 12 positive · 2 negative
AbbVie has delivered twice the market return with one-third the market risk.
“You're getting twice the market return for one-third of the market risk.”
Open the episode · AI Relief Rally, Nvidia Governance and CoreWeave EarningsListen at 30:46
Investors should wait to buy AbbVie at a lower price.
“I would just love to buy it cheaper.”
Open the episode · Tech Tumbles In Market Sell-Off… And Moderna’s Meltdown After Data Leak 10/22/26Listen at 31:28
Aldeyra’s potential AbbVie partnership would have approximately 60–40 economics.
“it would also allow them to go into a partnership where it's pretty much 60-40 AbbVie.”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 15:09
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
50 episodes featuring AbbVie, newest first
- Nov 20, 2026
Biotech weighs AI disruption against a stronger 2027 deal cycleBiotech HangoutNov 20, 2026 - Nov 17, 2026
Amazon backs AI expansion as NVIDIA leadership risk tests the tradeHalftime ReportNov 17, 2026 - Nov 16, 2026
Prepare for a crash without abandoning the marketRich Habits PodcastNov 16, 2026 - Nov 13, 2026
Biotech launches expose the gap between forecasts and adoptionBiotech HangoutNov 13, 2026 - Nov 13, 2026
Scarce capital creates openings in overlooked ASX small capsThe Rules of InvestingNov 13, 2026 - Nov 11, 2026
CoreWeave tests whether AI stocks can sustain their reboundHalftime ReportNov 11, 2026